Report Description of the France Oncology Drugs Market

Research Scope and Assumption

• The report provides the market value for the base year 2020 and a yearly forecast up to 2028 in terms of revenue (USD billion)


• The key industry dynamics, regulatory scenario, reimbursement scenario, major market trends, and drug markets are evaluated to understand their impacts on the demand for the forecast period. The growth rates were estimated using correlation, regression, and time-series analysis


• We have used the combination of top-down and bottom-up approach for market sizing, analyzing key regional markets, dynamics, and trends for various solutions, services, and end uses


• All market estimates and forecasts have been validated through primary interviews with the Key Industry Players (KIPs) and secondary analysis


• Inflation has not been accounted for in order to estimate and forecast the market


• Numbers may not add up due to rounding off

Research Objective:

• To analyze and forecast the market size of France Oncology Drugs Drugs market


• To classify and forecast France Oncology Drugs Market market based on application, drugs, project type, and application.


• To identify drivers and challenges for France Oncology Drugs market


• To examine competitive developments such as mergers and acquisitions, agreements, collaborations and partnerships, etc., in France Oncology Drugs market


• To conduct pricing analysis for France Oncology Drugs Drugs market


• To identify and analyze the profile of leading players operating in France Oncology Drugs market

Reason to buy the report:

• Facilitate decision-making based on strong current and forecast data for Atopic Dermatitis drug market


• Develop strategies based on the latest regulatory framework


• Strategically analyze micro-markets with respect to individual growth trends, future prospects, and their contribution to the market


• Analyze competitive developments such as expansions, investments, mergers & acquisitions, new product developments, and research & developments in the Atopic Dermatitis market


• Analyze the opportunities in the market for stakeholders and draw a competitive landscape for market leaders


• To strategically profile key players and comprehensively analyze their market shares and core competencies


• We have technically sound team which do a deep dive research and also provide strategy-based consulting analysis

France Oncology Drugs Market Executive Summary

The cancer incidence rate has increased to make it the second leading cause of death after cardiovascular disorders. Environmental factors such as smoking, changing diet patterns, urbanization, and extended post-reproductive lifespan are responsible for this phenomenon and consequently leading to the growth of the market.

Market Size and Key Findings

The France Oncology Drugs market size is at around USD xx billion in 2021 and is projected to reach USD xx billion in 2028, exhibiting a CAGR of xx% during the forecast period.

According to the World Health Organization (WHO), cancer is a growing burden and the number of new cancer cases is going to rise from 18.1 million in 2018 to 29.4 million by 2040. Therefore, the increasing prevalence of cancer is expected to boost the demand for the global oncology cancer drugs market during the forecast period.



Market Dynamics

Market Growth Drivers Analysis

The market is undergoing a significant growth rate due to the factors such as the rising prevalence of different cancers, increasing new drug launch and product approvals, and growing research activities by the pharma companies in this field. Furthermore, the rising awareness regarding cancer among the population is anticipated to favor the global market in the upcoming years.

Market Restraints

Chemotherapy drugs kill cancer cells but also damages normal body cells. This results in the various side effects for the patients. Among the most common side-effects are bone marrow suppression, gastrointestinal disorders, neuropathies, hair loss, fatigue, and skin disorders. Therefore, these adverse effects associated with the oncology drugs are negatively influencing the growth of the market.

COVID-19 impact on "France Oncology Drugs Market

The outbreak of COVID-19 has had a positive impact on this market globally. Certain market segments have witnessed a growth in demand for drugs with respect to the COVID-19 emergency.The pharmaceutical companies involved in this market have significantly improved their supply chain management, enhanced the capabilities of their R&D, and invested more their manufacturing management and quality control.

Competitive Landscape

Key Players

Key market players include Pierre Fabre, ENYO Pharma, Inovotion, Xenothera, Zionexa, Sanofi, Casters, Juvise Pharmaceutical, Cellectis, Ipsen Pharma and Others

Products in Pipeline

Sanofi and The University of Texas MD Anderson Cancer Center today announced a five-year strategic collaboration to accelerate the development of investigational treatments, including targeted and immune-therapies, for patients with cancer. The alliance will combine MD Anderson's clinical trials infrastructure and Sanofi's pipeline of investigational treatments to lead biomarker-driven clinical studies to better understand how novel cancer drugs work.

Notable Recent Deals

Sanofi, a French pharmaceutical giant, has signed a deal to buy the US-based company, Amunix, which is developing novel cancer treatments that could be the key to defeating this illness.

French drugmaker Ipsen SA (IPN.PA) would buy some assets of Merrimack Pharmaceuticals Inc (MACK.O), including pancreatic cancer drug Onivyde, for up to $1 billion, barely a month after the U.S. company stopped a breast cancer drug trial. The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsens portfolio, which has traditionally focused on endocrinology.

Victoria, British Columbia (CANADA) and Castres (FRANCE), October 07, 2021 Immunoprecise Antibodies Ltd. (the Company or IPA) (NASDAQ: IPA) (TSX Venture: IPA) and the Pierre Fabre pharmaceutical group announced today that IPAs subsidiary, Talem Therapeutics LLC (Talem), and Pierre Fabre have entered a multi-year, multi-target research collaboration with the goal to discover and develop therapeutics antibodies for up to nine targets. This strategic collaboration is expected to help expand Talems portfolio of novel antibodies across oncology. It adds to the variety of diverse relationships that the IPA group of companies holds across the pharmaceutical and biotechnology sector.

Healthcare Policies and Regulatory Landscape

Policy changes and Reimbursement scenario of France Oncology Drugs Services

France benefits from a universal healthcare system offering wide coverage and large access to drugs. Almost all of the new hematology/oncology cancer drugs assessed had a favorable opinion and are fully reimbursed (100%) by health insurance. A high proportion (66%) of CAV is recognized in oncology. Nevertheless, the over DRG list can inadvertently limit access to these new cancer drugs